Evidence-based pharmacotherapy of panic disorder

International Journal of Neuropsychopharmacology

Volumn 8, Issue 3, 2005, Pages 473-482

  Bakker, Abraham ^a   Van Balkom, Anton J L M ^b   Stein, Dan J ^c  

^a Robert Fleury Stichting   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Agoraphobia; Panic disorder; Pharmacotherapy; Treatment

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; CLONIDINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LITHIUM; LORAZEPAM; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; PAROXETINE; PHENELZINE; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; CONTROLLED STUDY; DRUG CHOICE; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; PANIC; PRIORITY JOURNAL; REVIEW;

ANTIDEPRESSIVE AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; MEDLINE; META-ANALYSIS; PANIC DISORDER;

EID: 22344438837     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145705005201     Document Type: Review

References (57)

1. APA (2000). Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision). Washington, DC: American Psychiatric Association.
2. Bakker A, van Balkom AJLM, Spinhoven P (2002). SSRIs versus TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatrica Scandinavica 106, 163-167.
3. Bakker A, van Balkom AJLM, Spinhoven P, Blaauw BMJW, van Dyck R (1998). Follow-up on the treatment of panic disorder with or without agoraphobia: a quantitative review. Journal of Nervous and Mental Disease 186, 414-419.
4. Bakker A, van Balkom AJLM, van Dyck R (2000). Selective serotonin reuptake inhibitors in the treatment of panic disorder and agoraphobia. International Clinical Psychopharmacology 15 (Suppl. 2), S25-S30.
5. Bakker A, van Dyck R, Spinhoven P, van Balkom AJLM (1999). Paroxetine, clomipramine and cognitive therapy in the treatment of panic disorder. Journal of Clinical Psychiatry 60, 831-838.
6. Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, Baldwin DS, den Boer JA, Kasper S, Shear MK (1998b). Consensus statement on panic disorder from the international consensus group on depression and anxiety. Journal of Clinical Psychiatry 59 (Suppl. 8), 47-54.
7. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP (1998a). Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. American Journal of Psychiatry 155, 36-42.
8. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ (2002). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World Journal Biological Psychiatry 3, 171-199.
9. Beauclair L, Fontaine R, Annable L, Holobow N, Chouinard G (1994). Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. Journal of Clinical Psychopharmacology 14, 111-118.
10. Bijl RV, van Zessen G, Ravelli A (1997). Psychiatric morbidity among adults in the Netherlands: the NEMESIS study. Prevalence of psychiatric disorders. Nederlands Tijdschrift voor Geneeskunde 141, 2453-2460.
11. Black DW, Wesner R, Bowers W, Gabel J (1993). A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Archives of General Psychiatry 50, 44-50.
12. Bourdon KH, Boyd JH, Rae DS, Burns BJ, Thompson JW, Locke BZ (1988). Gender differences in phobias: results of the ECA community survey. Journal of Anxiety Disorders 2, 227-241.
13. Boyer W (1995). Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. International Clinical Psychopharmacology 10, 45-49.
14. Burrows GD, Norman TR (1999). The treatment of panic disorder with benzodiazepines. In: Panic Disorder: Clinical Diagnosis, Management and Mechanisms (pp. 145-158). London: Martin Dunitz.
15. Cassano GB, Petracca A, Perugi G, Nisita C, Musetti L, Mengali F, McNair DM (1988). Clomipramine for panic disorder, I: the first 10 weeks of a long-term comparison with imipramine. Journal of Affective Disorders 14, 123-127.
16. Chignon JM, Lepine JP, Ades J (1993). Panic disorder in cardiac outpatients. American Journal of Psychiatry 150, 780-785.
17. Clark DM (1986). A cognitive approach to panic. Behaviour Research and Therapy 24, 461-470.
18. Cross National Collaborative Panic Study, Second Phase Investigators (1992). Drug treatment of panic disorder. British Journal of Psychiatry 160, 191-202.
19. de Beurs E, van Balkorn AJLM, Lange A, Koele P, van Dyck R (1995). Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. American Journal of Psychiatry 152, 683-692.
20. den Boer JA, Westenberg HGM (1988). Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. International Clinical Psychopharmacology 3, 59-74.
21. den Boer JA, Westenberg HGM, Kamerbeek WDJ (1987). Effect of a serotonin uptake inhibitor in anxiety disorders: a double-blind comparison of clomipramine and fluvoxamine. International Clinical Psychopharmacology 2, 21-32.
22. Eaton WW, Dryman A, Weissman MM (1991). Panic and phobia. In: Robins LN, Regier DA (Eds.), Psychiatric Disorders in America (pp. 155-179). New York: Free Press.
23. Eaton WW, Kessler RC, Wittchen HU, Magee WJ (1994). Panic and panic disorder in the United States. American Journal of Psychiatry 151, 413-420.
24. Emmelkamp PMG, Bouman T, Scholing HA (1992). Anxiety disorders: A Practitioner's Guide. Chichester: Wiley.
25. Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D (2001). Early coadministration of clonazepam with sertraline for panic disorder. Archives of General Psychiatry 58, 681-686.
26. Gorman JM (1997). The use of newer antidepressants for panic disorder. Journal of Clinical Psychiatry 58 (Suppl. 14), 54-58.
27. Hoehn-Saric R, McLeod D, Hipsley PA (1993). Effect of fluvoxamine on panic disorder. Journal of Clinical Psychopharmacology 13, 321-326.
28. Jonas JM, Cohon MS (1993). A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature. Journal of Clinical Psychiatry 54 (Suppl. 10), 25-45.
29. Katerndahl DA, Realini JP (1993). Lifetime prevalence of panic states. American Journal of Psychiatry 150, 246-249.
30. Lecrubier Y, Bakker A, Dunbar G, Judge R, and the Collaborative Paroxetine Panic Study Investigators (1997). A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatrica Scandinavica 95, 145-152.
31. Lydiard RB, Steiner M, Burnham D, Gergel I (1998). Efficacy studies of paroxetine in panic disorder. Psychopharmacology Bulletin 34, 175-182.
32. Marks IM (1987). Fears, Phobias and Rituals. Oxford, NY: Oxford University Press.
33. Marks IM, Swinson RP, Basoglu M, Kuch K, Noshirvani H, O'Sullivan G, Lelliott PT, Kirby M, McNamee G, Sengun S, Wickwire K (1993). Alprazolam and exposure alone and combined in panic disorder with agoraphobia. British Journal of Psychiatry 162, 776-787.
34. Mavissakalian M, Perel JM (1992). Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Archives of General Psychiatry 49, 318-323.
35. Mavissakalian M, Perel JM (2002). Duration of imipramine therapy and relapse in panic disorder with agoraphobia. Journal of Clinical Psychopharmacology 22, 294-299.
36. Michelson D, Lydiard RB, Pollack MH, Tamura RN, Hoog SL, Tepner R, Demitrack MA, Tollefson GD and the Fluoxetine Panic Disorder Study Group (1998). Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. American Journal of Psychiatry 155, 1570-1577.
37. Michelson D, Pollack M, Lydiard RB, Tamura R, Tepner R, Tollefson G and the Fluoxetine Panic Disorder Study Group (1999). Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. British Journal of Psychiatry 174, 213-218.
38. Milrod BL, Busch FN, Cooper AM, Shapiro T (1997). Manual of Panic-Focused Psychodynamic Psychotherapy. Washington, DC: American Psychiatric Association.
39. Modigh K, Westberg P, Eriksson E (1992). Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. Journal of Clinical Psychopharmacology 12, 251-261.
40. Nair NPV, Bakish D, Saxena B, Amin M, Schwartz G, West TEG (1996). Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Anxiety 2, 192-198.
41. Noyes R, Garvey MJ, Cook B, Suelzer M (1991). Controlled discontinuation of benzodiazepine treatment for patients with panic disorder. American Journal of Psychiatry 148, 517-523.
42. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Ohrstrom JK, Manniche PM (1995). Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. British Journal of Psychiatry 167, 374-379.
43. Otto MW, Tuby KS, Gould RA, McLean RY, Pollack MH (2001). An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. American Journal of Psychiatry 158, 1989-1992.
44. Papp LA, Schneier FR, Fyer AJ, Liebowitz MR, Gorman JM, Coplan JD, Campeas R, Fallon BA, Klein DF (1997). Clomipramine treatment of panic disorder: pros and cons. Journal of Clinical Psychiatry 58, 423-425.
45. Raj A, Sheehan DV (1987). Medical evaluation of panic attacks. Journal of Clinical Psychiatry 48, 309-313.
46. Rapaport MH, Wolkow RM, Clary CM (1998). Methodologies and outcomes from the sertraline multicenter flexible-dose trials. Psychopharmacology Bulletin 34, 183-189.
47. Rosenberg R (1999). Treatment of panic disorder with tricyclics and MAOIs. In: Panic Disorder: Clinical Diagnosis, Management and Mechanisms (pp. 125-144). London: Martin Dunitz.
48. Roy-Byrne PP, Stang P, Wittchen HU, Ustun B, Walters EE, Kessler RC (2000). Lifetime panic-depression co-morbidity in the National Comorbidity Survey. British Journal of Psychiatry 176, 229-235.
49. Seedat S, van Rheede van Oudtshoorn E, Muller JE, Mohr N, Stein DJ (2003). Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. International Clinical Psychopharmacology 18, 279-284.
50. Sharp DM, Power KG, Simpson RJ, Swanson V, Moodie E, Anstee JA, Ashford JJ (1996). Fluvoxamine, placebo, and cognitive behaviour therapy used alone and in combination in the treatment of panic disorder and agoraphobia. Journal of Anxiety Disorders 10, 219-242.
51. Stein MB, Asmundson GJ, Ireland D, Walker JR (1994). Panic disorder in patients attending a clinic for vestibular disorders. American Journal of Psychiatry 151, 1697-1700.
52. Tiller JWG, Bouwer C, Behnke K (1997). Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder. International Clinical Psychopharmacology 12 (Suppl. 6), S27-S30.
53. van Balkom AJLM, Bakker A, Spinhoven Ph, Blaauw BMJW, Smeenk S, Ruesink B (1997). A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. Journal of Nervous and Mental Disease 185, 510-516.
54. van Balkom AJLM, Nauta MCE, Bakker A (1995). Meta-analysis on the treatment of panic disorder with agoraphobia: review and re-examination. Clinical Psychology and Psychotherapy 2, 1-14.
55. Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T (1997). The effect of citalopram in panic disorder. British Journal of Psychiatry 170, 549-553.
56. Wiborg IM, Dahl AA (1996). Does brief dynamic psychotherapy reduce the relapse rate of panic disorder? Archives of General Psychiatry 53, 689-694.
57. Wilkinson G, Balestrieri M, Ruggeri M, Bellantuono C (1991). Meta-analysis of double-blind placebo controlled trials of antidepressants and benzodiazepines for patients with panic disorders. Psychological Medicine 21, 991-998.